Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Pembrolizumab

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.…

References (Sources)

Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Huang & Zhang, 2017 Current Cancer Therapy Reviews 13: 120-128
Pembrolizumab
Khoja et al. 2015
Review
Pembrolizumab: First Global Approval
Poole, 2014
Review
Safety & Efficacy of Pembrolizumab in Advanced, PD-L1 – Positive Cervical Cancer: Results From Phase Ib KEYNOTE-028 Trial
Frenel et al. 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
Hsu et al. 2017
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Hamid et al., 2013
Second- and third-generation drugs for immuno-oncology Treatment - The more the better?
Dempke et al. 2017 European Journal of Cancer 74: 55e72
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Pembrolizumab

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat

Links